BEYİN TÜMÖRÜ OLAN HASTADA NOCARDIA FARCINICA’NIN NEDEN OLDUĞU NADİR BİR LOKALİZE PULMONER NOKARDİYOZ OLGUSU

Year 2024, Volume: 87 Issue: 2, 176 - 179, 27.03.2024

Sevinç Vural , Tayfur Demiray , Salih Bilen , Özlem Aydemir , Mehmet Köroğlu

https://doi.org/10.26650/IUITFD.1386668

Abstract

Nocardia farcinica klinik örneklerden nadiren izole edilir ve diğer Nocardia türlerine göre daha virülan bir türdür. Bu makalede uzun süreli kortikosteroid kullanımı, kronik solunum yolu hastalığı ve beyin tümörü gibi risk faktörlerine sahip bir hastada Nocardia farcinica'nın neden olduğu nadir bir plevral ampiyem ve pnömoni olgusu değerlendirildi. N. farcinica'nın diğer Nocardia türlerinden ayrılması önemlidir, çünkü N. farcinica daha virülandır ve özellikle geniş spektrumlu sefalosporinlere yüksek derecede dirençlidir ve bu da tedaviyi zorlaştırabilir. Sonuç olarak, immünsüpresif ilaç kullanan ve eşlik eden hastalıkları olan hastalarda nonspesifik fizik muayene ve radyografik bulguların varlığında ayırıcı tanıda Nocardia enfeksiyonu gibi atipik etkenlerin akılda tutulması gerekmektedir.

Keywords

Nokardiyoz, Nocardia farcinica, plevral efüzyon, antibiyotik duyarlılık testi, bağışıklığı zayıflamış hastalar

A RARE CASE OF LOCALIZED PULMONARY NOCARDIOSIS CAUSED BY NOCARDIA FARCINICA IN A PATIENT WITH A BRAIN TUMOR

Abstract

Nocardia farcinica is rarely isolated from clinical specimens, and it is a more virulent strain than other types of Nocardia. In this report, we evaluated a rare case of pleural empyema and pneumonia caused by Nocardia farcinica in a patient who had risk factors such as long-term use of corticosteroids, chronic respiratory disease, and a brain tumor. The distinction of N. farcinica from other Nocardia species is important because N. farcinica is more virulent and highly resistant, especially to broad-spectrum cephalosporins, which can make treatment difficult. In conclusion, in the presence of nonspecific physical examination and radiographic findings in patients using immunosuppressives and having comorbid diseases, atypical causative agents such as Nocardia infection should be considered in the differential diagnosis.

Keywords

Nocardiosis, Nocardia farcinica, pleural effusion, antibiotic susceptibility test, immunocompromised patients

References

• Kandi V. Human Nocardia Infections: A review of pulmonary nocardiosis. Cureus 2015;7(8):e304. [CrossRef] google scholar
• Steinbrink J, Leavens J, Kauffman CA, Miceli MH. Manifestations and outcomes of Nocardia infections comparison of immunocompromised and non-immunocompromised adult patients. Medicine (United States) 2018;97(40):e12436. [CrossRef] google scholar
• Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010;38(2):89-97. [CrossRef] google scholar
• Bagüeste G, Porcel JM, Bagüeste G, Porcel JM. Pleural infection caused by Nocardia farcinica: two cases and review of the literature. Cureus 2021;13(4):e14697. [CrossRef] google scholar
• Torres OH, Domingo P, Pericas R, Boiron P, Montiel JA, Vâzquez G. Infection caused by Nocardia farcinica: case report and review. Eur J Clin Microbiol Infect Dis 2000;19(3):205-12. [CrossRef] google scholar
• Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006;19(2):259-82. [CrossRef] google scholar
• Budzik JM, Hosseini M, Mackinnon AC, Taxy JB. Disseminated Nocardia farcinica: Literature review and fatal outcome in an immunocompetent patient. Surg Infect (Larchmt) 2012;13(3):163-70. [CrossRef] google scholar
• Valdezate S, Garrido N, Carrasco G, Medina-Pascual MJ, Villalon P, Navarro AM, et al. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother 2017;72(3):754-61. [CrossRef] google scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance standards for susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes. 2nd edition. CLSI supplement M24S, 2023. google scholar
• Wilson JW. Nocardiosis: Updates and clinical overview. Mayo Clin Proc 2012;87(4):403-7. [CrossRef] google scholar
• Blackmon KN, Ravenel JG, Gomez JM, Ciolino J, Wray DW. Pulmonary nocardiosis: Computed tomography features at diagnosis. J Thorac Imaging 2011;26(3):224-9. [CrossRef] google scholar
• Margalit I, Lebeaux D, Tishler O, Goldberg E, Bishara J, Yahav D, et al. How do I manage nocardiosis? Clin Microbiol Infect 2021;27(4):550-8. [CrossRef] google scholar
• Girard V, Mailler S, Welker M, Arsac M, Celliere B, Cotte-Pattat PJ, et al. Identification of Mycobacterium spp. and Nocardia spp. from solid and liquid cultures by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). Diagn Microbiol Infect Dis 2016;86(3):277-83. [CrossRef] google scholar
• Lebeaux D, Bergeron E, Berthet J, Djadi-Prat J, Mouniee D, Boiron P, et al. Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010-2015. Clin Microbiol Infect 2019;25(4):489-95. [CrossRef] google scholar
• Wang H, Zhu Y, Cui Q, Wu W, Li G, Chen D, et al. Epidemiology and antimicrobial resistance profiles of the Nocardia species in China, 2009 to 2021. Microbiol Spectr 2022; 10(2):e0156021. [CrossRef] google scholar